Gilead Sciences, Inc. ranks in the top quartile of its peer group, with a broadly solid profile across the main structural dimensions. The trend setup is mixed, though short-term momentum remains constructive. The market is broadly confirming the structural profile.
Peer-relative scores, weakest to strongest
Gilead Sciences develops biopharmaceutical therapies, focusing on treatments for HIV, hepatitis, and oncology. The company has an established product portfolio and steady cash flows.
The market prices Gilead on stable earnings and defensive qualities, not on dynamic growth or innovation upside. With an operating margin of 33.2%, Gilead shows solid profitability, but revenue growth of just 2.1% is below the sector’s innovation leaders—so the market treats it as a defensive value play, not a growth story. In biopharma, Gilead is valued for its reliable cash flows, but its pipeline is seen as less dynamic than research-driven peers, which maintains its discount status. The market actively assigns Gilead a valuation that reflects stability and dependable performance, deliberately avoiding any premium for future growth potential—underscoring its focus on predictability over upside. Only a clear innovation breakthrough in the pipeline or significant revenue acceleration could break the defensive valuation framing.
Break down GILD's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.